Skip to main content

Table 2 Patients comparison based on the presence or absence of ≥ 40% PPG > 160 mg/dL

From: Prevalence of postprandial hyperglycaemia in basal insulin-treated patients with type 2 diabetes mellitus with controlled fasting glycaemia and elevated glycosylated haemoglobin

Patients with at least 40% PPG measurements > 160 mg/dL No (N = 38) Yes (N = 55) P-value
Sex (male/female) 19/19 (50.0/50.0%) 33/19 (60.0/50.0%) 0.3982 (a)
Age (years) 65.0 (10.8) 64.0 (10.6) 0.6776 (b)
BMI (kg/m2) 30.1 (6.0) 29.7 (4.6) 0.7069 (b)
Systolic blood pressure (mmHg) 140.1 (16.3) 137.7 (15.2) 0.4653 (b)
Diastolic blood pressure (mmHg) 79.9 (9.5) 76.6 (8.8) 0.0885 (b)
Total cholesterol (mg/dL) 166.2 (32.5) 163.6 (30.8) 0.7034 (b)
Triglycerides (mg/dL) 148.0 (90.2) 153.7 (101.5) 0.7816 (b)
LDL cholesterol (mg/dL) 88.8 (34.1) 91.8 (27.8) 0.6394 (b)
HDL colesterol (mg/dL) 51.7 (19.6) 43.8 (11.5) 0.0318 (b)
Time since diagnosis (years) 14.5 (8.9) 17.3 (8.0) 0.1231 (b)
 ≤ 2 years 3 (7.9%) 0 (0.0%) 0.0302 (c)
 2.1 to 5 years 3 (7.9%) 2 (3.6%)
 5.1 to 10 years 6 (15.8%) 8 (14.5%)
 > 10 years 26 (68.4%) 45 (81.8%)
HbA1c (%) 7.8 (0.5) 8.0 (0.5) 0.0912 (b)
HbA1c (mmol/mol) 62 (5) 64 (5)
Treatment with basal insulin: final dose (units/day) 31.1 (16.1) 31.1 (17.6) 0.9869 (a)
 Years of treatment 5.0 (4.7) 5.6 (4.4) 0.5474 (b)
Treatment with ADO 33 (86.8%) 49 (89.1%) 0.7543 (a)
 Years of treatment 9.2 (7.5) 11.7 (7.1) 0.1283 (b)
Treatment with metformin 30 (78.9%) 45 (81.8%) 0.7927 (a)
 Years of treatment 9.8 (7.6) 10.4 (6.6) 0.7361 (b)
Treatment with DPP-4 Inhibitor 8 (21.1%) 20 (36.4%) 0.1673 (a)
 Years of treatment 1.9 (1.5) 2.6 (1.8) 0.2983 (b)
Treatment with sulfonylurea 8 (21.1%) 21 (38.2%) 0.1110 (a)
 Years of treatment 6.7 (4.9) 12.7 (7.2) 0.0379 (b)
  1. Data are shown as n (%) or mean (SD). (a) Exact-Fisher, (b) independent T-student, (c) exact-Mantel–Haenszel
  2. Italic values indicate statistically significant comparison